Global Innovative Platforms (GIPL) Revenue (2025 - 2026)
Global Innovative Platforms' (GIPL) quarterly Revenue came in at $50700.0 in Q2 2026, down 52.39% quarter-over-quarter from $106500.0 in Q1 2026.
Analysis
Global Innovative Platforms (GIPL) Revenue (2025 - 2026) Analysis & Trends
Global Innovative Platforms has disclosed Revenue across 2 years of filings, most recently posting $50700.0 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 1.22 Bn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 2.47 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 1.37 Bn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 396.75 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | 7.19 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | 50,700.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50,700.00 |
| Mar 31, 2026 | 106,500.00 |
| Dec 31, 2025 | 30,000.00 |